

Moazzam Shahzad

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/6993502/publications.pdf>

Version: 2024-02-01

57
papers

153
citations

1684188

5
h-index

1281871

11
g-index

57
all docs

57
docs citations

57
times ranked

98
citing authors

#	ARTICLE	IF	CITATIONS
1	Chronic graft-versus-host disease presenting as acute polymyositis: A case series and systematic review. Transplant Immunology, 2022, 70, 101520.	1.2	6
2	Impact of COVID-19 in hematopoietic stem cell transplant recipients: A systematic review and meta-analysis. Transplant Infectious Disease, 2022, 24, .	1.7	28
3	Gender disparities in the National Institutes of Health funding for hematologic malignancies and cellular therapies. Leukemia and Lymphoma, 2022, 63, 1708-1713.	1.3	6
4	Top 100 Cited Articles on Hematopoietic Stem Cell Transplantation: A Bibliometric Analysis. Transplantation and Cellular Therapy, 2022, 28, S453-S454.	1.2	0
5	Outcomes of Autologous Stem Cell Transplantation in Primary Plasma Cell Leukemia: A Systematic Review and Meta-Analysis. Transplantation and Cellular Therapy, 2022, 28, S412-S413.	1.2	0
6	Outcomes with Allogeneic Hematopoietic Stem Cell Transplantation in TP53-Mutated Acute Myeloid Leukemia: A Systematic Review and Meta-Analysis. Transplantation and Cellular Therapy, 2022, 28, S119.	1.2	0
7	Socioeconomic and Racial Barriers to CD19 Chimeric Antigen Receptor T Cell Therapy (CART) Access. Transplantation and Cellular Therapy, 2022, 28, S208.	1.2	0
8	Outcomes with Allogeneic Hematopoietic Stem Cell Transplantation in TP53-Mutated Myelodysplastic Syndromes: A Systematic Review and Meta-Analysis. Transplantation and Cellular Therapy, 2022, 28, S122.	1.2	0
9	Outcomes of Allogeneic Hematopoietic Stem Cell Transplantation in Primary Plasma Cell Leukemia: A Systematic Review and Meta-Analysis. Transplantation and Cellular Therapy, 2022, 28, S416-S417.	1.2	0
10	Outcomes with Chimeric Antigen Receptor T-Cell Therapy in Relapsed or Refractory Acute Myeloid Leukemia: A Systematic Review and Meta-Analysis. Transplantation and Cellular Therapy, 2022, 28, S204.	1.2	0
11	Impact of CD34+ Graft Cell Dose on Outcomes after Allogeneic Peripheral Blood Stem Cell Transplantation: A Systemic Review and Meta-Analysis. Transplantation and Cellular Therapy, 2022, 28, S262-S263.	1.2	0
12	Outcomes with Allogeneic Hematopoietic Stem Cell Transplant in Therapy-Related Acute Myeloid Leukemia: A Systematic Review and Meta-Analysis. Transplantation and Cellular Therapy, 2022, 28, S114.	1.2	0
13	Socioeconomic and Racial Disparity in Chimeric Antigen Receptor T Cell Therapy Access. Transplantation and Cellular Therapy, 2022, 28, 358-364.	1.2	40
14	Outcomes after venetoclax with hypomethylating agents in myelodysplastic syndromes: a systematic review and meta-analysis. Leukemia and Lymphoma, 2022, 63, 2671-2678.	1.3	0
15	Role of biogenetic markers in differentiation and prognosis of giant cell tumor: A systemic review.. Journal of Clinical Oncology, 2021, 39, e23514-e23514.	1.6	0
16	Outcomes with COVID-19 in patients with hematopoietic stem cell transplant and cellular therapy: A systemic review and meta-analysis.. Journal of Clinical Oncology, 2021, 39, e18611-e18611.	1.6	1
17	Acute polymyositis presenting as chronic graft-versus-host disease: A systemic review.. Journal of Clinical Oncology, 2021, 39, e19025-e19025.	1.6	0
18	Outcomes with COVID-19 in hematopoietic stem cell transplant and cellular therapy patients.. Journal of Clinical Oncology, 2021, 39, 7033-7033.	1.6	0

#	ARTICLE	IF	CITATIONS
19	Outcomes with venetoclax in myelodysplastic syndromes: A systematic review.. Journal of Clinical Oncology, 2021, 39, e19035-e19035.	1.6	0
20	Outcomes with preemptive donor lymphocyte infusions after allogeneic hematopoietic stem cell transplantation for acute myeloid leukemia and myelodysplastic syndromes: A systematic review and meta-analysis.. Journal of Clinical Oncology, 2021, 39, e19014-e19014.	1.6	2
21	Outcomes with CD34 stem cell boost for poor graft function after allogeneic hematopoietic stem cell transplantation for hematologic malignancies: A systemic review and meta-analysis.. Journal of Clinical Oncology, 2021, 39, e19021-e19021.	1.6	1
22	Gender disparities in National Institute of Health funding for hematologic malignancies, hematopoietic stem cell transplantation, and cellular therapeutics.. Journal of Clinical Oncology, 2021, 39, 11020-11020.	1.6	0
23	Profile and management of toxicity of selinexor and belantamab mafodotin for the treatment of relapsed/refractory multiple myeloma: A systematic review.. Journal of Clinical Oncology, 2021, 39, e20014-e20014.	1.6	0
24	Management of light chain deposition disease: A systematic review.. Journal of Clinical Oncology, 2021, 39, e20042-e20042.	1.6	0
25	Management of Relapsed Hairy Cell Leukemia: A Systematic Review of Novel Agents and Targeted Therapies. Clinical Lymphoma, Myeloma and Leukemia, 2021, 21, 659-666.	0.4	1
26	Impact of SARS-CoV-2 in Hematopoietic Stem Cell Transplantation and Chimeric Antigen Receptor T Cell Therapy Recipients. Transplantation and Cellular Therapy, 2021, 27, 796.e1-796.e7.	1.2	42
27	Advances in viral oncolytics for treatment of multiple myeloma – a focused review. Expert Review of Hematology, 2021, 14, 1071-1083.	2.2	3
28	Outcomes with CD34-Selected Stem Cell Boost for Poor Graft Function after Allogeneic Hematopoietic Stem Cell Transplantation: A Systematic Review and Meta-Analysis. Transplantation and Cellular Therapy, 2021, 27, 877.e1-877.e8.	1.2	20
29	S3297â€ŒEffect of Gastrointestinal Hemorrhage in Patients Admitted With Gastrointestinal Lymphomas. American Journal of Gastroenterology, 2021, 116, S1359-S1359.	0.4	0
30	Treatment Outcomes for Follicular Lymphoma with Progression of Disease within 24 Months of Front-Line Therapy: A Systematic Review. Blood, 2021, 138, 4521-4521.	1.4	0
31	Outcomes with Interferon in Essential Thrombocythemia: A Systematic Review and Meta-Analysis. Blood, 2021, 138, 3147-3147.	1.4	0
32	Use of Endpoints in Phase III Randomized Controlled Trials for Acute Myeloid Leukemia over the Last 15 Years: A Systematic Review. Blood, 2021, 138, 4389-4389.	1.4	0
33	Evolution in Resource Utilization for Unique Toxicities Related to Chimeric Antigen Receptor T Cell Therapy from 2017 to 2020: A Database Review. Blood, 2021, 138, 4844-4844.	1.4	0
34	Outcomes of Tyrosine Kinase Inhibitors Maintenance Therapy with or without Allogeneic Hematopoietic Stem Cell Transplantation in Philadelphia Positive Acute Lymphoblastic Leukemia in First Complete Remission: A Systematic Review and Meta-Analysis. Blood, 2021, 138, 3961-3961.	1.4	0
35	Outcomes with Chimeric Antigen Receptor T-Cell Therapy in Relapsed or Refractory Acute Myeloid Leukemia: A Systematic Review and Meta-Analysis. Blood, 2021, 138, 4825-4825.	1.4	0
36	Outcomes with Chimeric Antigen Receptor T-Cell Therapy in Relapsed/Refractory Chronic Lymphocytic Leukemia: A Systematic Review and Meta-Analysis. Blood, 2021, 138, 4683-4683.	1.4	0

#	ARTICLE	IF	CITATIONS
37	Outcomes with Hematopoietic Stem Cell Transplantation in Secondary Hemophagocytic Lymphohistiocytosis: A Systematic Review and Meta-Analysis. Blood, 2021, 138, 3963-3963.	1.4	0
38	Safety and Cost Effectiveness of Chimeric Antigen Receptor T Cell Therapy in the Outpatient Setting. Blood, 2021, 138, 2823-2823.	1.4	0
39	Outcomes with Venetoclax in Relapsed Acute Myeloid Leukemia after Allogeneic Hematopoietic Stem Cell Transplantation: A Systemic Review and Meta-Analysis. Blood, 2021, 138, 4410-4410.	1.4	0
40	Outcomes with Mismatched Unrelated Donor Allogeneic Hematopoietic Stem Cell Transplantation: A Systematic Review and Meta-Analysis. Blood, 2021, 138, 1848-1848.	1.4	0
41	Use of Endpoints in Phase III Randomized Controlled Trials for Hematopoietic Stem Cell Transplantation over the Last 15 Years: A Systematic Review. Blood, 2021, 138, 4910-4910.	1.4	0
42	Outcomes with Interferon in Polycythemia Vera: A Systematic Review and Meta-Analysis. Blood, 2021, 138, 3659-3659.	1.4	0
43	Outcomes with Natural Killer Cells Infusion after Allogeneic Hematopoietic Stem Cell Transplantation: A Systematic Review and Meta-Analysis. Blood, 2021, 138, 1847-1847.	1.4	0
44	Outcomes with Mismatched Unrelated Donor Allogeneic Hematopoietic Stem Cell Transplantation Following Reduced Intensity Conditioning: A Systematic Review and Meta-Analysis. Blood, 2021, 138, 2863-2863.	1.4	0
45	Impact of Natural Killer Cells Reconstitution on Outcomes after Allogeneic Hematopoietic Stem Cell Transplantation: A Systematic Review and Meta-Analysis. Blood, 2021, 138, 4880-4880.	1.4	0
46	Top 100 Cited Articles on Hematopoietic Stem Cell Transplantation: A Bibliometric Analysis. Blood, 2021, 138, 4790-4790.	1.4	0
47	Outcomes with "Off the Shelf" Allogeneic CD19 Chimeric Antigen Receptor T Cell Therapy for Hematological Malignancies: A Systematic Review and Meta-Analysis. Blood, 2021, 138, 4831-4831.	1.4	0
48	Comparison of Efficacy and Safety Profile of Allogeneic Versus Autologous CD19 Chimeric Antigen Receptor T Cell Therapy in Hematological Malignancies: A Systematic Review and Meta-Analysis. Blood, 2021, 138, 4824-4824.	1.4	0
49	Bispecific T-Cell Engager Antibodies in Multiple Myeloma- a Systematic Review of Phase 1 Clinical Trials. Blood, 2021, 138, 4775-4775.	1.4	0
50	Efficacy of Venetoclax Based Regimens in Relapsed Refractory Multiple Myeloma: A Systematic Review and Meta-Analysis. Blood, 2020, 136, 39-40.	1.4	2
51	Spleen and Symptom Responses of JAK Inhibitors in Myelofibrosis; A Systematic Review of Phase 2 and 3 Trials. Blood, 2020, 136, 26-27.	1.4	0
52	A Systematic Review of Daratumumab Based Four Drug Regimen for Newly Diagnosed Multiple Myeloma in Phase III Clinical Trials. Blood, 2020, 136, 36-37.	1.4	1
53	Systematic Review of Phase III Trials of Daratumumab Based Regimens in Relapsed Refractory Multiple Myeloma. Blood, 2020, 136, 4-5.	1.4	0
54	A Systematic Review of Phase III Clinical Trials of Daratumumab Addition to Standard Care Regimen for Newly Diagnosed Multiple Myeloma. Blood, 2020, 136, 7-7.	1.4	0

#	ARTICLE	IF	CITATIONS
55	Efficacy of Daratumumab Based Regimens Compared to Standard of Care for Transplant Ineligible Newly Diagnosed Multiple Myeloma in Phase III Clinical Trials: A Meta-Analysis. Blood, 2020, 136, 32-33.	1.4	0
56	Azacitidine Maintenance Following Allogeneic Hematopoietic Stem Cell Transplantation in Patients with Myelodysplastic Syndrome and Acute Myeloid Leukemia: A Systematic Review. Blood, 2020, 136, 29-30.	1.4	0
57	Efficacy of Daratumumab Based Regimens Compared to Standard of Care for Transplant Eligible Multiple Myeloma in Phase III Clinical Trials: A Meta-Analysis. Blood, 2020, 136, 36-36.	1.4	0